Using the power of metabolism to treat cancer
Faeth was founded by a team of world-leading scientists to bring metabolically-driven cancer treatments to patients. Faeth’s programs span across multiple tumor types and leverage our knowledge of human and tumor metabolism to increase the efficacy of our cancer drugs.
Groundbreaking research led by Faeth’s founders show that by precisely modulating nutrients, we can alter the tumor and systemic metabolism to favorably impact cancer drugs.
Faeth’s therapeutic programs combine traditional anti-cancer drugs with precision nutrition diets designed to increase the efficacy of the drugs.
Our lead program, FTH-001, targets the Pi3K/mTOR pathway, the most frequently mutated pathway in solid tumors. This pathway regulates cell growth and metabolism, and drives cancer proliferation. To date, efforts to inhibit this pathway have been unsuccessful and lead to unacceptable patient toxicities.
Faeth’s FTH-002 program combines our FTH-002 therapeutic with metabolic optimization through diet to deprive tumors of the nutrients they need to grow.